BMY ▼ -1.5% - Bristol-Myers Squibb Company
$BMY Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
06-NOV-2026 04:01 PM ET
Share this post
More filings for $BMY
BMY ▲ +2.0% - Bristol-Myers Squibb CompanyOct 29, 2026BMY ▼ -0.6% - Bristol-Myers Squibb CompanyOct 23, 2026BMY ▼ -0.7% - Bristol-Myers Squibb CompanyOct 23, 2026BMY ▲ +4.6% - Bristol-Myers Squibb CompanyOct 12, 2026BMY ▲ +4.6% - Bristol-Myers Squibb CompanyOct 12, 2026BMY ▲ +0.2% - Bristol-Myers Squibb CompanyOct 8, 2026
View full $BMY filing history →💬 Comments
Loading comments…
Leave a comment